HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

Related Keywords

,Tyrosine Kinase Inhibitors ,Unresectable Hepatocellular Carcinoma ,Hepatocellular Carcinoma ,Hcc ,Dotace ,Transarterial Chemoembolization ,Lenvatinib ,Launch Study ,Emerald 1 Study ,Durvalumab ,Bevacizumab ,Pembrolizumab ,